Focalis Bio is a biotech company developing cutting-edge gene therapies targeting focal refractory epilepsy (FRE)
Our goal is to make patients with FRE seizure free
Nicolas Koebel, CEO of Focalis Bio explains our mission to develop transformative gene therapies for focal refractory epilepsy.
-
Our mission
Our mission is to make patients with focal refractory epilepsy seizure-free.
-
Our people
Our team brings world-leading expertise in epilepsy research & development and gene therapy commercialisation.
-
Our approach
Our scientific strategy revolves around the targeted delivery of gene therapy to the seizure focus.
-
Life with focal refractory epilepsy
